**Title: Starboard Calls for Strategic Overhaul at Pfizer Amid Criticisms of Research and M&A Failures**
Activist investor Starboard Value is urging a strategic overhaul at Pfizer, citing significant shortcomings in the company’s research direction and M&A strategy. Starboard criticizes Pfizer for failing to effectively harness the substantial profits gained from its COVID-19 vaccine, alleging this has led to a loss of tens of billions in market value.
Starboard’s analysis points to deficiencies in both Pfizer’s research development pipeline and its handling of mergers and acquisitions. The activist investor suggests that this mismanagement has weakened Pfizer’s competitive position in the biotech market. Concerns regarding the strategic allocation of COVID-19 revenues and insufficient focus on innovative research advancements have been highlighted.
Starboard is advocating for a realignment in Pfizer’s leadership and an enhancement in strategic planning to better capitalize on market opportunities and drive shareholder value. The call for change reflects a broader concern among investors about the company’s recent performance and future direction.
Access full insights via [BioPharma Dive](https://www.biopharmadive.com/news/pfizer-starboard-value-activist-presentation-management-criticism/730584/).